Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: ER-positive Breast Cancer|HER2-negative Breast Cancer|Stage IIB Breast Cancer|Stage III Breast Cancer
Interventions: DRUG: Elacestrant|DRUG: Tamoxifen|DRUG: Letrozole 2.5mg|DRUG: Anastrozole 1mg|DRUG: Exemestane 25 MG
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Collaborators: Breast International Group|Menarini Group